RUNX2 and breast carcinoma: The work presented here, which shows that RUNX2 stimulates cell motility of breast adenocarcinoma cells, corroborates the concept that RUNX2 represents a prognostic marker for breast cancer progression that is mechanistically linked to the metastatic potential of the cells in which it is expressed.